Capricor Therapeutics (CAPR) Equity Average: 2011-2025
Historic Equity Average for Capricor Therapeutics (CAPR) over the last 15 years, with Sep 2025 value amounting to $94.4 million.
- Capricor Therapeutics' Equity Average rose 136.74% to $94.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.4 million, marking a year-over-year increase of 136.74%. This contributed to the annual value of $84.0 million for FY2024, which is 388.73% up from last year.
- Latest data reveals that Capricor Therapeutics reported Equity Average of $94.4 million as of Q3 2025, which was down 18.82% from $116.3 million recorded in Q2 2025.
- Over the past 5 years, Capricor Therapeutics' Equity Average peaked at $136.6 million during Q1 2025, and registered a low of $471,754 during Q3 2023.
- In the last 3 years, Capricor Therapeutics' Equity Average had a median value of $20.5 million in 2024 and averaged $50.4 million.
- Its Equity Average has fluctuated over the past 5 years, first slumped by 97.24% in 2023, then spiked by 8,354.34% in 2024.
- Quarterly analysis of 5 years shows Capricor Therapeutics' Equity Average stood at $34.1 million in 2021, then tumbled by 60.04% to $13.6 million in 2022, then fell by 23.51% to $10.4 million in 2023, then skyrocketed by 926.85% to $106.9 million in 2024, then soared by 136.74% to $94.4 million in 2025.
- Its last three reported values are $94.4 million in Q3 2025, $116.3 million for Q2 2025, and $136.6 million during Q1 2025.